Teladoc 19% selloff presents buying opportunity, says JPMorganJPMorgan analyst Lisa Gill views the 19% pullback since March 21 in shares of Teladoc as a buying opportunity. The analyst does not have a fundamental reason to point to for the selloff and believes the company's underlying fundamentals are unchanged. Gill has heard some concerns following the Forbes article earlier this week that questioned Teladoc's use of an adjusted EBITDA metric. She notes, however, that nearly all of the companies within her coverage universe focus investors on an adjusted EBITDA or adjusted EBIT. With the acquisitions that Teladoc has done over the past few years, amortization has grown significantly, and excluding that helps to better understand the underlying growth of the business, Gill tells investors in a research note. The analyst continues to see "significant runway" in the telehealth space going forward and keeps an Overweight rating on Teladoc with an $80 price target.Read more at: (source) $TDOChttps://thefly.com/landingPage...Tiger's Take: On our watchlist an d we wrote about this 3 days ago. Longer-term this could be a good investment, but do some due diligence first. Like one of my subscribers mentioned today, maybe $50 level is the floor/support. $TDOC, Teladoc Health, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or comments.